Stemedica Cell Technologies, Inc.
- Home
- Companies
- Stemedica Cell Technologies, Inc.
- Services
- Services of Ischemic Stroke
Services of Ischemic Stroke
Every year in the United States alone, almost 800,000 people suffer a stroke. Of that number, more than 137,000 will die from a stroke, making it the third highest cause of death in the United States. Eighty-seven percent of all strokes are ischemic, which are caused by blood clots.* Stemedica has completed a Phase I/IIA clinical trial to assess the safety and efficacy of using adult bone-marrow derived mesenchymal stem cells for ischemic stroke patients.
Most popular related searches
clinical trial
stroke patient
bone marrow
blood clotting
blood clot
stem cell
bone marrow cell
clinical assessment
The clinical trial was conducted at the University of California, San Diego with Michael Levy, M.D. as the principal investigator, at Gilbert Hospital under the leadership of Dr. Nabil Dib, MD and at the University of California Irvine under the leadership of Steven Cramer, MD.